Openbookopenbook
Equity
Vyne Therapeutics Inc(VYNE)
USD --+0.00%
Reward34Low
Risk64Medium-High
📊75%Data
Revenue growing 40% YoY
VYNE
+0.0 · +0.00%
USD · NASDAQ
Vyne Therapeutics Inc | Healthcare
Capital Destroyer
Market Cap:19.99M
ℹ️
Reward Rating
34
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
64
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on VYNE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.00.

What is Vyne Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.

VYNE · Verdict

Limited reward · elevated risk

VYNE's standout is balance sheet; volatility and cash flow weigh on the picture.

Based on 88% data coverage

VYNE · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet89/100

    Current ratio 12.53

Watchouts 5

  • Volatility5/100

    Weak vs peers

  • Cash flow6/100

    -5811% free-cash-flow margin

  • Profitability8/100

    -4646% net margin · -71% ROE

  • Growth35/100

    Rev +6.1% CAGR · earnings +4.5%

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Vyne Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 19.99M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap19.99M
P/E RatioN/A
Dividend YieldN/A
52 Week High2.602
52 Week Low0.281
Last AnnualDecember
IPO Date1/25/2018
IncorporatedUSA
Shares Outstanding33M
No. of Employees13
IndustryBiotechnology
ExchangeNASDAQ
Beta2.028
CurrencyUSD
Websitevynetherapeutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.